Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01665053 · ClinicalTrials.gov registry record · Phase 3
The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,684
- Enrollment target
NCT01665053 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,684 participants.
The verdict
NCT01665053, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,684 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate).
Interventions
- DEVICE PROMUS Element Plus
- DEVICE SYNERGY
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,684 participants |
| Start Date | 2012-11 |
| Est. Completion | 2018-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01665053
The ClinicalTrials.gov registry entry for NCT01665053 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,684 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PROMUS Element Plus is the first listed.
NCT01665053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01665053 about?
NCT01665053 is a clinical study titled "The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)". The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diamete...
What is the current status of trial NCT01665053?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,684 participants. The study started on 2012-11. Estimated completion is 2018-12-22.
What interventions are being tested in trial NCT01665053?
The interventions under investigation include: PROMUS Element Plus (DEVICE), SYNERGY (DEVICE).
Who is sponsoring clinical trial NCT01665053?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.